IR@PKUHSC  > 北京大学第一临床医学院  > 风湿免疫科
学科主题临床医学
Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension
Jing, Zhi-Cheng1; Strange, Geoff2; Zhu, Xian-Yang3; Zhou, Da-Xin4; Shen, Jie-Yan5; Gu, Hong6; Yang, Zhen-Kun7; Pan, Xin8; Xiang, Mei-Xiang9; Yao, Hua10; Zhao, Dong-Bao11; Dalton, Brad S.12; Zhang, Zhuo-Li13; Wang, Yong14; Cheng, Xian-Sheng15; Yang, Yue-Jin15
关键词Pulmonary Arterial Hypertension Bosentan
刊名JOURNAL OF HEART AND LUNG TRANSPLANTATION
2010-02-01
DOI10.1016/j.healun.2009.09.020
29期:2页:150-156
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems ; Respiratory System ; Surgery ; Transplantation
资助者Actelion Pharmaceuticals ; Actelion Pharmaceuticals
研究领域[WOS]Cardiovascular System & Cardiology ; Respiratory System ; Surgery ; Transplantation
关键词[WOS]CONGENITAL HEART-DISEASE ; RECEPTOR ANTAGONIST BOSENTAN ; EISENMENGER-SYNDROME ; EXERCISE CAPACITY ; 1ST-LINE BOSENTAN ; THERAPY ; SURVIVAL ; REGISTRY ; ADULTS ; MANAGEMENT
英文摘要

BACKGROUND: Bosentan has an established role in the management of pulmonary arterial hypertension (PAH). This clinical trial assessed the benefits of bosentan in the Chinese population.

METHODS: We investigated the efficacy and safety of bosentan in 92 Chinese citizens (mean +/- standard deviation age, 29.0 +/- 3.8 years) with PAH for a minimum of 12 weeks. All received bosentan (62.5 mg twice daily) for 4 weeks; then, patients who weighed <40 kg received 62.5 mg bosentan twice daily and patients who weighed >40 kg received 125 mg twice daily. All patients were eligible to continue bosentan beyond 12 weeks. The primary end point was a chance in exercise capacity from baseline to 12 and 24 weeks. Secondary end points included a change in World Health Organization (WHO) functional class and changes in cardiopulmonary hemodynamics.

RESULTS: At baseline, 66 patients (72%) were in WHO functional class III; presentation was 37 (40%) with idiopathic PAH (iPAH), 34 (37%) with PAH related to congenital heart disease (CHD), and 21 (23%) with PAH related to connective tissue disease (CTD). Exercise capacity increased to 67.8 m after 12 weeks and 92.6 m after 24 weeks (p < 0.001). After 24 weeks, WHO functional class decreased (-0.8 +/- 0.6; p < 0.001), mean pulmonary artery pressure and pulmonary vascular resistance decreased (p < 0.01), ana cardiac output increased (p < 0.001). Twelve patients (13%) experienced at least 1 adverse event.

CONCLUSIONS: Bosentan improved exercise capacity, functional class, and cardiopulmonary hemodynamics in this patient cohort and was well tolerated. J Heart Lung Transplant 2010;29:150-6 (C) 2010 International Society for Heart and Lung Transplantation. All rights reserved.

语种英语
资助者Actelion Pharmaceuticals ; Actelion Pharmaceuticals
WOS记录号WOS:000274755700002
引用统计
被引频次:12[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/56695
专题北京大学第一临床医学院_风湿免疫科
作者单位1.Guangzhou Gen Hosp, Dept Cardiol, Guangzhou, Guangdong, Peoples R China
2.Beijing Shijitan Hosp, Dept Pulm Vasc Dis, Beijing, Peoples R China
3.Monash Univ, Clayton, Vic 3800, Australia
4.Ruijin Hosp, Dept Cardiol, Shanghai, Peoples R China
5.Tongji Univ, Dept Pulm Circulat, Shanghai Pulm Hosp, Sch Med, Shanghai 200092, Peoples R China
6.Gen Hosp Shenyang Mil Command, Dept Congenital Heart Dis, Shenyang, Peoples R China
7.Fudan Univ, Dept Cardiol, Zhongshan Hosp, Shanghai 200433, Peoples R China
8.Shanghai Jiao Tong Univ, Dept Cardiol, Renji Hosp, Sch Med, Shanghai 200030, Peoples R China
9.Capital Univ Med Sci, Dept Pediat, Beijing Anzhen Hosp, Beijing, Peoples R China
10.Shanghai Jiao Tong Univ, Dept Cardiol, Shanghai Chest Hosp, Sch Med, Shanghai 200030, Peoples R China
11.Zhejiang Univ, Dept Cardiol, Affiliated Hosp 2, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China
12.Second Mil Med Univ, Dept Rheumatol, Changhai Hosp, Shanghai, Peoples R China
13.Univ Tasmania, Sch Human Life Sci, Hobart, Tas 7001, Australia
14.Beijing Univ, Dept Rheumatol, Hosp 1, Beijing 100871, Peoples R China
15.Beijing Fu Wai Hosp, Dept Cardiol, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Jing, Zhi-Cheng,Strange, Geoff,Zhu, Xian-Yang,et al. Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension[J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION,2010,29(2):150-156.
APA Jing, Zhi-Cheng.,Strange, Geoff.,Zhu, Xian-Yang.,Zhou, Da-Xin.,Shen, Jie-Yan.,...&Yang, Yue-Jin.(2010).Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension.JOURNAL OF HEART AND LUNG TRANSPLANTATION,29(2),150-156.
MLA Jing, Zhi-Cheng,et al."Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension".JOURNAL OF HEART AND LUNG TRANSPLANTATION 29.2(2010):150-156.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jing, Zhi-Cheng]的文章
[Strange, Geoff]的文章
[Zhu, Xian-Yang]的文章
百度学术
百度学术中相似的文章
[Jing, Zhi-Cheng]的文章
[Strange, Geoff]的文章
[Zhu, Xian-Yang]的文章
必应学术
必应学术中相似的文章
[Jing, Zhi-Cheng]的文章
[Strange, Geoff]的文章
[Zhu, Xian-Yang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。